We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc.
Efruxifermin (EFX) with GLP-1RA significantly reduces hepatic fat fraction and improves fibrosis in MASH and T2D patients. The study involved 31 patients over 12 weeks, showing EFX enhances GLP ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of ...
Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis ...
The study highlights the efficacy of efruxifermin (EFX) in patients with F4 MASH, showing statistically significant improvements in fibrosis stages over a 96-week period. The treatment’s ability ...
Akero Therapeutics (AKRO) released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin, or EFX ...
Akero Therapeutics reported Monday strong results from a nearly two-year, placebo-controlled study showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by the ...
Over the 15 months in between, more study participants responded to Akero’s drug, called efruxifermin. Overall, 29% of people given the highest tested dose of efruxifermin experienced ...
Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcohol-related liver disease. MASH is linked to a ...
Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...